Skip to main content
Clinical Trials/NCT04602559
NCT04602559
Completed
Not Applicable

Exploratory Study to Evaluate the Clinical Benefits of Wearing the Panty MOBIDERM in Patients With Pelvic and/or Genital Lymphedema : OLYMPY Study

Thuasne3 sites in 1 country32 target enrollmentDecember 3, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lymphedema of Genitalia
Sponsor
Thuasne
Enrollment
32
Locations
3
Primary Endpoint
Quality of life (QoL): Patient's opinion on Global Impression of Change (PGI-C)
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Lymphedema (LO) is a chronic and disabling condition that affects quality of life. This pathology has a physical, psychological, social and professional impact. Pelvic or genital lymphedema (LP/LG) is the result of a dysfunction of the lymphatic system in the genital area that can occur following surgery, radiation therapy, tumor, infections affecting the inguinal lymph nodes or related lymphatic pathways (secondary LP/LG). Urogenital cancers are the major cause of secondary LP/LG. It is difficult to have an accurate estimate of the prevalence of LP/LG. LP/LG can be painful, the edema very bulky and disharmonious. The patient is facing with significant physical and psychological difficulties. The volume of the lymphedema can be important, causing discomfort, rubbing when walking or during physical activities, disrupting daily life and may constitute a major handicap.

Detailed Description

Currently, there is no reference treatment which is validated for these lymphedemas, and few recommendations from the competent authorities or learned societies are available. There is no solution available on the market which covers all the needs and expectations of patients and healthcare professionals. The Panty MOBIDERM is a standard pelvic compressive orthosis that should promote lymphatic drainage, then reduce the volume of edema, and contributing to an overall improvement in the patients' quality of life.

Registry
clinicaltrials.gov
Start Date
December 3, 2020
End Date
July 9, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Thuasne
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Primary or secondary pelvic or genital lymphedema of stage II ou III according to the criteria defined by the International Society of Lymphology.
  • Patient with discomfort related to lymphedema
  • Presence of the Stemmer's sign if applicable
  • Patient with a morphology compatible with the 6 sizes of the MOBIDERM Panty (Minimum and maximum pelvic circumference: 88 and 129 cm respectively)
  • Patient who gave signed, informed, voluntary consent prior to any intervention in the study
  • Patient affiliated to the General regime of the Social Security or covered by a similar health insurance system

Exclusion Criteria

  • Pregnant woman or woman of childbearing age without contraception
  • Patient with surgery of the small pelvis or genitals performed within the last 3 months prior to inclusion or any surgery scheduled during the study period
  • Patient with hydrocoele
  • Patient who had intensive reduction therapy for lower limb lymphedema within the last month
  • Patient with a contraindication to compression, such as untreated infection, skin irritation, recent thrombosis (\< 3 months), obliterative arterial disease of the lower limbs with a systolic pressure index \< 0.6, phlegmatia coerulea dolens (painful blue phlebitis with arterial compression) in the thigh area
  • Patient with decompensated heart failure
  • Patient with a known allergy to the components used in the Panty
  • Patient with untreated or escaped cancer
  • Patient with a postectomy within the last 3 months prior to inclusion
  • Patient with significant edema localized only to the labia minora

Outcomes

Primary Outcomes

Quality of life (QoL): Patient's opinion on Global Impression of Change (PGI-C)

Time Frame: 90 days

The patient's impression of overall change is measured by the Patient's opinion on Global Impression of Change questionnaire. The scale has 7 levels of response : "no change or condition has got worse" that is the worst outcome (= 1 point) "almost the same, hardly any change at all" (= 2 points); "a little better , but no noticeable change" (= 3 points); "somewhat better, but the change has not made any real difference" (= 4 points); "moderately better, and a slight but noticeable change" (= 5 points); "better, and a definite improvement that has made a real and worthwhile difference (=6 points) "A great deal better, and a considerable improvement that has made all the diiference" (=7 points) The highest score corresponds to the most improvement in quality of life.

Secondary Outcomes

  • Characteristic of pelvic lymphedema : Genital Lymphedema Score (GLS)(day : 0, 30, 90)
  • Pelvic/genital lymphedema perimetry for men only : Whitaker tool(day : 0, 30, 90)
  • Swelling, tension, discomfort and feeling of heaviness :Visual Analog Scale (VAS)(day : 0, 30, 90)
  • Pain : Visual Analog Scale (VAS)(day : 0, 30, 90)
  • Day and NIght Compliance to treatment(day : 30,90)
  • Satisfaction about the device: specific self questionnaire(Day : 30)
  • Safety: Adverse Device Effects(day : 0, 30, 90)
  • Quality of life (QoL): Lymphedema Quality of Life Inventory (LyQLI) self-questionnaire(day : 0, 30, 90)
  • Impact of lymphedema on sexual life : Visual Analog Scale (VAS)(day : 0, 30, 90)
  • Doctors' opinion on the change of patient's health condition (Clinical Global Impression -Improvement)(day : 30, 90)
  • Sleep quality : Jenkins self-questionnaire(day : 0, 30, 90)
  • Quality of life (QoL): EQ-5D-5L questionnaire(day : 0, 30, 90)

Study Sites (3)

Loading locations...

Similar Trials